SMTI vs. INGN, ZJYL, COCH, AVNS, CERS, AVIR, SOPH, KMDA, SHCR, and LYRA
Should you be buying Sanara MedTech stock or one of its competitors? The main competitors of Sanara MedTech include Inogen (INGN), Jin Medical International (ZJYL), Envoy Medical (COCH), Avanos Medical (AVNS), Cerus (CERS), Atea Pharmaceuticals (AVIR), SOPHiA GENETICS (SOPH), Kamada (KMDA), Sharecare (SHCR), and Lyra Therapeutics (LYRA). These companies are all part of the "medical" sector.
Sanara MedTech (NASDAQ:SMTI) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.
Sanara MedTech currently has a consensus target price of $44.00, suggesting a potential upside of 17.96%. Inogen has a consensus target price of $13.67, suggesting a potential upside of 68.52%. Given Inogen's higher probable upside, analysts clearly believe Inogen is more favorable than Sanara MedTech.
In the previous week, Sanara MedTech had 7 more articles in the media than Inogen. MarketBeat recorded 9 mentions for Sanara MedTech and 2 mentions for Inogen. Inogen's average media sentiment score of 0.93 beat Sanara MedTech's score of 0.36 indicating that Inogen is being referred to more favorably in the news media.
Sanara MedTech has higher earnings, but lower revenue than Inogen. Sanara MedTech is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
Sanara MedTech has a net margin of -6.62% compared to Inogen's net margin of -32.46%. Sanara MedTech's return on equity of -11.12% beat Inogen's return on equity.
8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 55.2% of Sanara MedTech shares are owned by insiders. Comparatively, 0.6% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Sanara MedTech has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Inogen received 369 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 70.70% of users gave Inogen an outperform vote while only 53.13% of users gave Sanara MedTech an outperform vote.
Summary
Sanara MedTech beats Inogen on 10 of the 17 factors compared between the two stocks.
Get Sanara MedTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Sanara MedTech Competitors List
Related Companies and Tools